IL154060A0 - Mon-sedating barbiturate compounds as neuroprotective agents - Google Patents
Mon-sedating barbiturate compounds as neuroprotective agentsInfo
- Publication number
- IL154060A0 IL154060A0 IL15406001A IL15406001A IL154060A0 IL 154060 A0 IL154060 A0 IL 154060A0 IL 15406001 A IL15406001 A IL 15406001A IL 15406001 A IL15406001 A IL 15406001A IL 154060 A0 IL154060 A0 IL 154060A0
- Authority
- IL
- Israel
- Prior art keywords
- mon
- neuroprotective agents
- sedative
- sedating barbiturate
- barbiturate compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22167200P | 2000-07-26 | 2000-07-26 | |
PCT/US2001/023420 WO2002007729A1 (en) | 2000-07-26 | 2001-07-26 | Non-sedating barbiturate compounds as neuroprotective agents |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154060A0 true IL154060A0 (en) | 2003-07-31 |
Family
ID=22828824
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15406001A IL154060A0 (en) | 2000-07-26 | 2001-07-26 | Mon-sedating barbiturate compounds as neuroprotective agents |
IL154060A IL154060A (en) | 2000-07-26 | 2003-01-20 | Non-anesthetic barbiturate compounds as preparations for moisturizers |
IL16501704A IL165017A0 (en) | 2000-07-26 | 2004-11-03 | Non-sedating barbiturate compounds as neuroprotective agents |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL154060A IL154060A (en) | 2000-07-26 | 2003-01-20 | Non-anesthetic barbiturate compounds as preparations for moisturizers |
IL16501704A IL165017A0 (en) | 2000-07-26 | 2004-11-03 | Non-sedating barbiturate compounds as neuroprotective agents |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1311270B1 (xx) |
JP (1) | JP5047442B2 (xx) |
CN (2) | CN100522172C (xx) |
AT (1) | ATE383159T1 (xx) |
AU (2) | AU8077801A (xx) |
BR (1) | BR0112775A (xx) |
CA (1) | CA2416535C (xx) |
DE (1) | DE60132337T2 (xx) |
ES (1) | ES2300349T3 (xx) |
HK (1) | HK1100814A1 (xx) |
IL (3) | IL154060A0 (xx) |
MX (1) | MXPA03000824A (xx) |
PT (1) | PT1311270E (xx) |
WO (1) | WO2002007729A1 (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
CN100522172C (zh) * | 2000-07-26 | 2009-08-05 | 塔罗制药工业有限公司 | 非镇静巴比土酸盐化合物在制备神经保护剂中的用途 |
US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US6939873B2 (en) | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
CN1896084A (zh) * | 2002-01-30 | 2007-01-17 | 塔罗制药工业有限公司 | 非镇静性巴比土酸衍生物 |
ATE546136T1 (de) | 2002-10-11 | 2012-03-15 | Baxter Int | Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln |
ES2315569T3 (es) * | 2002-12-11 | 2009-04-01 | Taro Pharmaceutical Industries Ltd. | Procedimiento de tratamiento de trastornos del movimiento usando derivados de acido barbiturico. |
EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
EP2755945A1 (en) * | 2011-09-12 | 2014-07-23 | Council of Scientific & Industrial Research | ARYLATED beta-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF |
CN102863579B (zh) * | 2012-09-14 | 2014-02-05 | 东南大学 | 一种巴比妥酸螯合树脂及其制备方法和应用 |
CN108351352B (zh) | 2015-10-05 | 2021-09-10 | 北卡罗来纳-查佩尔山大学 | 用于多路测定的解码方法及相关流体设备、试剂盒和固体支持物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL69722A (en) * | 1983-09-14 | 1986-09-30 | Taro Pharma Ind | Oxopyrimidine derivatives and pharmaceutical compositions containing them |
US4833148A (en) * | 1987-04-09 | 1989-05-23 | Washington University | Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury |
US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
CN100522172C (zh) * | 2000-07-26 | 2009-08-05 | 塔罗制药工业有限公司 | 非镇静巴比土酸盐化合物在制备神经保护剂中的用途 |
-
2001
- 2001-07-26 CN CNB2006100813267A patent/CN100522172C/zh not_active Expired - Fee Related
- 2001-07-26 AT AT01959195T patent/ATE383159T1/de not_active IP Right Cessation
- 2001-07-26 PT PT01959195T patent/PT1311270E/pt unknown
- 2001-07-26 BR BR0112775-6A patent/BR0112775A/pt not_active Application Discontinuation
- 2001-07-26 EP EP01959195A patent/EP1311270B1/en not_active Expired - Lifetime
- 2001-07-26 MX MXPA03000824A patent/MXPA03000824A/es active IP Right Grant
- 2001-07-26 CA CA2416535A patent/CA2416535C/en not_active Expired - Fee Related
- 2001-07-26 CN CNB018151426A patent/CN1329032C/zh not_active Expired - Fee Related
- 2001-07-26 DE DE60132337T patent/DE60132337T2/de not_active Expired - Lifetime
- 2001-07-26 AU AU8077801A patent/AU8077801A/xx active Pending
- 2001-07-26 AU AU2001280778A patent/AU2001280778B2/en not_active Ceased
- 2001-07-26 IL IL15406001A patent/IL154060A0/xx unknown
- 2001-07-26 WO PCT/US2001/023420 patent/WO2002007729A1/en active IP Right Grant
- 2001-07-26 JP JP2002513464A patent/JP5047442B2/ja not_active Expired - Fee Related
- 2001-07-26 ES ES01959195T patent/ES2300349T3/es not_active Expired - Lifetime
-
2003
- 2003-01-20 IL IL154060A patent/IL154060A/en not_active IP Right Cessation
-
2004
- 2004-11-03 IL IL16501704A patent/IL165017A0/xx unknown
-
2007
- 2007-06-05 HK HK07105924.3A patent/HK1100814A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002007729A1 (en) | 2002-01-31 |
ATE383159T1 (de) | 2008-01-15 |
CN1329032C (zh) | 2007-08-01 |
WO2002007729A9 (en) | 2002-08-08 |
HK1100814A1 (en) | 2007-09-28 |
PT1311270E (pt) | 2008-04-15 |
AU2001280778B2 (en) | 2004-09-02 |
ES2300349T3 (es) | 2008-06-16 |
JP2004517808A (ja) | 2004-06-17 |
EP1311270A1 (en) | 2003-05-21 |
MXPA03000824A (es) | 2004-11-01 |
IL154060A (en) | 2013-05-30 |
EP1311270B1 (en) | 2008-01-09 |
DE60132337T2 (de) | 2009-02-12 |
CA2416535C (en) | 2010-11-16 |
DE60132337D1 (de) | 2008-02-21 |
IL165017A0 (en) | 2005-12-18 |
CA2416535A1 (en) | 2002-01-31 |
CN1872067A (zh) | 2006-12-06 |
JP5047442B2 (ja) | 2012-10-10 |
EP1311270A4 (en) | 2006-04-12 |
CN100522172C (zh) | 2009-08-05 |
AU8077801A (en) | 2002-02-05 |
BR0112775A (pt) | 2003-12-30 |
CN1461219A (zh) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100814A1 (en) | Use of non-sedating barbiturate compounds in preparation of neuroprotective agents | |
AU7315301A (en) | Compounds and compositions for delivering active agents | |
MXPA02007690A (es) | Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide. | |
MXPA01008611A (es) | Compuestos y composiciones para suministrar agentes activos. | |
PL347671A1 (en) | Compounds and compositions for delivering active agents | |
NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
HUP0302792A3 (en) | Cyclopropyl-fused pyrrolidine-based onhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds | |
GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
MXPA02011632A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1. | |
AP2001002264A0 (en) | Sustained release formulations for growth hormone secretagogues. | |
IL112518A0 (en) | Thyroid hormone fast dispersing pharmaceutical composition | |
NZ514574A (en) | Novel method of treatment | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
SE0202857D0 (sv) | Method and compositions for preventing hormone induced adverse effects | |
EP1708685A4 (en) | GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
MXPA04010392A (es) | Composiciones de cromo y metodos para utilizar las mismas para inhibir resistencia a insulina inducida por droga. | |
BR0314898A (pt) | Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica | |
MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
IL162614A (en) | Alpha tocopherol esters for use in treating culture-borne cell disease by aerosol administration | |
MY153713A (en) | A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate | |
AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
EP1905441A3 (en) | Non-sedating barbiturate compounds as neuroprotective agents | |
WO2006009602A3 (en) | Multiple ppi dosage form |